QualityStocks would like to highlight Northwest Biotherapeutics, Inc. (OTCBB: NWBO), a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The company is developing dendritic cell-based vaccines. Their lead clinical trial is a 240-patient trial in newly diagnosed Glioblastoma multiforme (“GBM”), the most aggressive and lethal form of brain cancer. The company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. They have also conducted a Phase I/II trial with DCVax®-L for recurrent metastatic ovarian cancer.
In the company’s news yesterday,
Northwest Biotherapeutics made a joint announcement with the Fraunhofer IZI Institute that 13-month collaborative efforts have resulted in the completion of “significant milestones” in NW Bio’s DCVax®-L program for brain cancer in Germany.
NW Bio said it is now positioned to soon advance with both its clinical trial program and hospital exemption cases under the compassionate use cases, per the German Drug Act.
“It has been a very intensive process for well over a year to complete these important milestones in Germany,” Linda Powers, CEO of NW Bio stated in the press release. “We are grateful to have such a strong and close working relationship with our partner, Fraunhofer IZI, and to benefit from their extensive expertise with German and European regulatory requirements. We are also excited to now be poised to move forward in the near term with our clinical trial program and Hospital Exemption cases in Germany, with its population of nearly 85 million people.”
NW Bio’s contract manufacturer, Cognate BioServices, teamed with Fraunhofer IZI to carry out the four-month long technology transfer of the manufacturing process for DCVax®-L.
The milestones include the completion and filing of all necessary documentation and applications as part of the regulatory process; and the parties are now awaiting the final inspection required before the manufacturing authorization can be granted and manufacturing can proceed for clinical trials and hospital exemption cases. The inspection is scheduled for June 2012.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.